This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
Novo Nordisk experimental obesity pill has mild-to-moderate side effects in trial
Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...
Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
Novo Nordisk experimental obesity pill has mild-to-moderate side effects in early trial
Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an ...
The Financial Express11d
Novo Nordisk experimental obesity pill found to be safe and tolerable in early trial
Existing obesity drugs like Wegovy and Eli Lilly's Zepbound are injectable. Pills require larger amounts of active ...
Business Insider11d
The next big market for weight-loss drugs: children
Danish drugmaker Novo Nordisk's weight loss drug Saxenda has helped children aged ... The US adult obesity rate was about 40% from 2017 to 2020, and Goldman Sachs researchers estimated last ...